| Followers | 74 |
| Posts | 3928 |
| Boards Moderated | 0 |
| Alias Born | 03/23/2013 |
Sunday, August 12, 2018 1:30:13 PM
Now here are three main reasons for the current pps:
Dilution and insiders selling.
Funds portfolio adjustment to reduce risk exposure.
Fish oil Meta Analysis.
None of the above changes anything about EPA sience and RI chances of success. IMO recent sell off created a unique opportunity to accumulate shares at nice discount so close to a binary event.
Now to be clear although it's possible I'm not betting on some crazy efficacy results but IMO results will be substantial enough to generate huge interest and demand for AMRN stock with imminent BO in the end.
These 3 main reasons should be MAJOR reasons for failure.
This chart helps explain why. Notice the red down bars as prices sink below the important 200- and 50-day moving averages:
Momentum is gaining steam – unfortunately to the downside.
You can see the price response to the Cantor F. induced rally that failed at the iceline, and subsequent kill shot by management’s secondary offering. The stock has not recovered. You are right, funds suddenly perceived the investment as risky and began to bail (especially when insiders sold). From then on, smart money chose to sell at resistance vs buy at support. There is not one green bar (like we see at the beginning of other rallies) since the January top.
Finally, the Fish Oil Meta Analysis. What do you think trial participants are going to do when they hear of all these fish oil studies failing to prove any significance in preventing CVD? Do you think they’ll continue to choke down 4 horse pills? Some no doubt were aware that Amarin failed to meet efficacy and/or conditions sufficient to halt at two separate interims. Do you think they remained dedicated to their mineral oil after that news?
Now to be clear although it's possible I'm not betting on some crazy efficacy results
Yes,.. you are. It has truly become a gamble/bet.
IMO results will be substantial enough to generate huge interest and demand for AMRN stock with imminent BO in the end.
I highly doubt any BP is interested, given their ‘black eye’ history with the FDA. Thus the preparation to GIA, and try and survive.
Based on my calculations, there is now a 94% chance of a leak (someone knows something is wrong) and only a 4% chance of recovery leading to a successful outcome. People always know and they tell their friends. Of course, if you are drunk on the Kool-Aid, you will ignore all this.
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
